235 related articles for article (PubMed ID: 26531242)
1. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B reactivation is a rare event among patients with resolved infection undergoing anti-CD20 antibodies in monotherapy without antiviral prophylaxis: results from the HEBEM study.
Marzo B; Vidal-Jordana A; Castilló J; Robles-Sanchez MA; Otero-Romero S; Tintore M; Montalban X; Buti M; Riveiro-Barciela M
J Neurol; 2024 Jan; 271(1):134-140. PubMed ID: 37695530
[TBL] [Abstract][Full Text] [Related]
3. Impact of Hepatitis B Surface and Core Antibody Levels on Hepatitis B Virus Reactivation.
Ohkubo M; Seo E; Doki K; Suzuki Y; Sekine I; Homma M
Biol Pharm Bull; 2024; 47(5):941-945. PubMed ID: 38735754
[TBL] [Abstract][Full Text] [Related]
4. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.
Buti M; Manzano ML; Morillas RM; García-Retortillo M; Martín L; Prieto M; Gutiérrez ML; Suárez E; Gómez Rubio M; López J; Castillo P; Rodríguez M; Zozaya JM; Simón MA; Morano LE; Calleja JL; Yébenes M; Esteban R
PLoS One; 2017; 12(9):e0184550. PubMed ID: 28898281
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection.
Kotake T; Satake H; Okita Y; Hatachi Y; Hamada M; Omiya M; Yasui H; Hashida T; Kaihara S; Inokuma T; Tsuji A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):63-68. PubMed ID: 29984542
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Cessation of Nucleos(t)ide Analog Administration on Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study.
Onozawa M; Kusumoto S; Najima Y; Hashimoto H; Okada K; Tamaki M; Tanaka M; Sato T; Takahashi T; Hatano K; Onodera K; Moriuchi Y; Yakushijin K; Kanda J; Nagafuji K; Ogata M; Nakano N; Tamori A; Mizokami M
Transplant Cell Ther; 2024 Mar; 30(3):330.e1-330.e8. PubMed ID: 38242442
[TBL] [Abstract][Full Text] [Related]
7. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis.
He MK; Peng C; Zhao Y; Liang RB; Lai ZC; Kan A; Li QJ; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M
Cancer Immunol Immunother; 2021 Nov; 70(11):3207-3216. PubMed ID: 33813646
[TBL] [Abstract][Full Text] [Related]
8. De novo hepatitis B infection following liver transplantation with core antibody positive grafts: The role of surface antibody status in guiding long-term prophylaxis.
Busebee B; Myhre L; Mara K; Aqel B; Taner T; Watt KD
Clin Transplant; 2024 Feb; 38(2):e15263. PubMed ID: 38375953
[TBL] [Abstract][Full Text] [Related]
9. Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.
Çelik M; Baba C; Irmak Ç; Özakbaş S; Avkan-Oğuz V
J Neurol; 2024 Apr; ():. PubMed ID: 38578494
[TBL] [Abstract][Full Text] [Related]
10. Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment.
Axiaris G; Zampeli E; Michopoulos S; Bamias G
World J Gastroenterol; 2021 Jul; 27(25):3762-3779. PubMed ID: 34321842
[TBL] [Abstract][Full Text] [Related]
11. The Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Receiving Tocilizumab: A Systematic Review and Meta-Analysis.
Ko PH; Kuo MH; Kao IT; Wu CY; Tseng CW; Shao SC
Viruses; 2024 Jan; 16(1):. PubMed ID: 38257778
[TBL] [Abstract][Full Text] [Related]
12. Frequent reactivations of anti-HBe-positive chronic hepatitis B in patients with no demonstrable HBV DNA in serum by polymerase chain reaction.
Lee HS; Yoon JH; Kim CY
Korean J Intern Med; 1995 Jul; 10(2):103-7. PubMed ID: 7495767
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B.
Hong J; Lee J; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Sinn DH; Ahn MJ
Cancer; 2024 May; 130(9):1693-1701. PubMed ID: 38165808
[TBL] [Abstract][Full Text] [Related]
14. Case reports of latent HBV hepatitis in patients after neurosurgical treatment for hypothalamic and pituitary tumors.
Niizuma K; Ogawa Y; Kogure T; Tominaga T
BMC Infect Dis; 2020 Mar; 20(1):230. PubMed ID: 32188424
[TBL] [Abstract][Full Text] [Related]
15. Outcome of Multiple Myeloma Patients With Hepatitis B Surface Antigen: Korean Multiple Myeloma Working Party 2103 Study.
Yi JH; Lee JL; Lee YJ; Kang HJ; Park YH; Yuh YJ; Lim SN; Kim HJ; Jung SH; Lee JJ; Cho HJ; Moon JH; Yhim HY; Kim K
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):e50-e57.e2. PubMed ID: 37973459
[TBL] [Abstract][Full Text] [Related]
16. Current and future use of antibody-based passive immunity to prevent or control HBV/HDV infections.
Gehring AJ; Salimzadeh L
Antiviral Res; 2024 Jun; 226():105893. PubMed ID: 38679166
[TBL] [Abstract][Full Text] [Related]
17. Case report: Recombinant human type II tumour necrosis factor receptor-antibody fusion protein induced occult hepatitis B virus reactivation leading to liver failure.
Qin Y; Zhou W; Zhou X; Li H
J Int Med Res; 2024 May; 52(5):3000605241252580. PubMed ID: 38760056
[TBL] [Abstract][Full Text] [Related]
18. Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus.
Lin Z; Zhang X; Zhou Y; Chen C; He LN; Li H; Wang Y; Chen T; Hong S; Zhang L
Cancer Immunol Immunother; 2022 May; 71(5):1247-1255. PubMed ID: 34647153
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B reactivation and rituximab in the oncology practice.
Villadolid J; Laplant KD; Markham MJ; Nelson DR; George TJ
Oncologist; 2010; 15(10):1113-21. PubMed ID: 20930099
[TBL] [Abstract][Full Text] [Related]
20. Analysis of hepatitis B virus infection in 1424 patients with different pathological types of lymphoma (2018-2022): A real-world, retrospective study.
Li Z; Guo W; Zhao Y; Wang H; Guo J; Li Z; Wang B; Cao L; Xu J; Young KH; Bai O
Cancer Med; 2024 May; 13(10):e7284. PubMed ID: 38752442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
